Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo

We transferred the complementarity determining regions from a murine monoclonal antibody that neutralizes infection by respiratory syncytial virus (RSV) to a human IgG1 monoclonal antibody. The resulting reshaped human antibody lost affinity for RSV, but an additional alteration to one of the framework regions restored binding affinity and specificity. This second generation reshaped human monoclonal antibody cross-reacted with all clinical isolates of RSV tested and both prevented disease and cured mice even when administered four days after infection. We expect the antibody will prove useful in the management of this major childhood disease.

[1]  R. Chanock,et al.  Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. , 1985, Virus research.

[2]  J. Seidman,et al.  Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments , 1980, Cell.

[3]  A. Yeager,et al.  Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection. , 1977, American journal of diseases of children.

[4]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[5]  H. Waldmann,et al.  Tolerance to rat monoclonal antibodies. Implications for serotherapy , 1986, The Journal of experimental medicine.

[6]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[7]  L M Amzel,et al.  Preliminary refinement and structural analysis of the Fab fragment from human immunoglobulin new at 2.0 A resolution. , 1981, The Journal of biological chemistry.

[8]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[9]  G. Klein,et al.  EB virus-induced B lymphocyte cell lines producing specific antibody , 1977, Nature.

[10]  Robert O. Fox,et al.  Recombinant antibodies possessing novel effector functions , 1984, Nature.

[11]  Larrick Jw,et al.  Prospects for the therapeutic use of human monoclonal antibodies. , 1986 .

[12]  R. Chanock,et al.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. , 1973, American journal of epidemiology.

[13]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[14]  F. Eckstein,et al.  Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis. , 1986, Nucleic acids research.

[15]  K. James,et al.  Human monoclonal antibody production. Current status and future prospects. , 1987, Journal of immunological methods.

[16]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Treisman,et al.  Transcription maps of polyoma virus-specific RNA: analysis by two-dimensional nuclease S1 gel mapping. , 1980, Methods in enzymology.

[18]  P. Gardner,et al.  Respiratory syncytial virus infection in north-east England. , 1976, British medical journal.

[19]  R. Chanock,et al.  Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children , 1982, Infection and immunity.

[20]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Huber,et al.  Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI. , 1974, European journal of biochemistry.

[22]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[23]  J. Kilmartin,et al.  Rat monoclonal antitubulin antibodies derived by using a new nonsecreting rat cell line , 1982, The Journal of cell biology.

[24]  G. Taylor,et al.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice. , 1984, Immunology.

[25]  J. Waner,et al.  Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic , 1987, The Pediatric infectious disease journal.

[26]  E. Walsh,et al.  Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. , 1985, The Journal of infectious diseases.

[27]  T. Honjo,et al.  Structure of human immunoglobulin gamma genes: implications for evolution of a gene family , 1982, Cell.

[28]  M. Neuberger,et al.  The immunogenicity of chimeric antibodies , 1989, The Journal of experimental medicine.

[29]  G. Winter,et al.  Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Prince,et al.  Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children , 1987, Antimicrobial Agents and Chemotherapy.

[31]  M. Neuberger.  Making novel antibodies by expressing transfected immunoglobulin genes , 1985 .

[32]  H. Waldmann,et al.  REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H , 1988, The Lancet.

[33]  M. Ogilvie,et al.  Maternal antibody and respiratory syncytial virus infection in infancy , 1981, Journal of medical virology.